GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (LTS:0GP7) » Definitions » 14-Day RSI

Medivir AB (LTS:0GP7) 14-Day RSI : 1.98 (As of Jun. 10, 2024)


View and export this data going back to . Start your Free Trial

What is Medivir AB 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-06-10), Medivir AB's 14-Day RSI is 1.98.

The industry rank for Medivir AB's 14-Day RSI or its related term are showing as below:

LTS:0GP7's 14-Day RSI is ranked worse than
86.51% of 1564 companies
in the Biotechnology industry
Industry Median: 45.075 vs LTS:0GP7: 1.98

Competitive Comparison of Medivir AB's 14-Day RSI

For the Biotechnology subindustry, Medivir AB's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Medivir AB's 14-Day RSI falls into.



Medivir AB  (LTS:0GP7) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medivir AB  (LTS:0GP7) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Medivir AB 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Medivir AB's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB (LTS:0GP7) Business Description

Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.

Medivir AB (LTS:0GP7) Headlines

No Headlines